CAEL-101

Drug Profile

CAEL-101

Alternative Names: 11 1F4; CAEL 101; Ch mAb 11-1F4

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator Caelum Biosciences
  • Developer Caelum Biosciences; Columbia University; National Cancer Institute (USA)
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis; Amyloid light-chain amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Amyloid light-chain amyloidosis

Most Recent Events

  • 01 Jun 2017 Caelum Biosciences and Patheon enter into a manufacturing agreement for Amyloid light chain amyloidosis
  • 04 May 2017 Updated efficacy data from a phase Ia/Ib trial in Amyloidosis released by Fortress Biotech
  • 06 Apr 2017 CAEL-101 receives Orphan Drug status for Amyloidosis (Diagnosis) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top